Abstract:Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure–activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01196.Molecular formula strings (CSV)FLT3 homology (PDB)Molecular modeling information involved in compound Lu-46 with FLT3-WT (PDB)Molecular modeling information involved in compound Lu-46 with FLT3-F691L (PDB)Molecular modeling information involved in compound 31 with FLT3-WT (PDB)Molecular modeling information involved in compound 31 with FLT3-F691L (PDB)Molecular modeling information involved in compound 41 with FLT3-WT (PDB)Molecular modeling information involved in compound 55 with FLT3-WT (PDB)Molecular modeling information involved in compound 55 with FLT3-F691L (PDB)Molecular modeling information involved in compound 67 with FLT3-WT (PDB)Molecular modeling information involved in compound 67 with FLT3-F691L (PDB)Molecular modeling information involved in compound 67 with FLT3-D835V (PDB)Molecular modeling information involved in compound 67 with FLT3-Y842H (PDB)Molecular modeling information involved in compound 67 with FLT3-N676D (PDB)Figures for the manuscript (ZIP)Average root-mean-square deviation (rmsd) of backbone atoms of various FLT3 protein models and compound 55 throughout MD simulations; halogen bond analysis of 55 bound to FLT3-WT and FLT3-F691L models during MD simulations (40–50 ns); cell viability of HCD57, HCD57-FLT3-ITD, and HCD57-FLT3-D835Y cells after treating with compound 67; average rmsd of backbone atoms of various FLT3 protein models and compound 67 throughout the MD simulations; halogen bond analysis of 67 bound to various FLT3 models during MD simulations (90–100 ns); apoptosis induction and cell cycle arrest effects of compound 67 on HCD57, HCD-FLT3-ITD, and HCD-FLT3-D835Y cells at 100 nM concentration; peripheral blood counts of MV4-11 xenograft tumor mice treated with compound 67; and 1H NMR and 13C NMR spectra for target compound molecular formula strings (PDF)This article has not yet been cited by other publications.

Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors

Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations

Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects

Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC)

Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted Mir-150 Nanoparticles.

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives

Recent advances in FLT3 inhibitors for acute myeloid leukemia.

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Abstract 4009: Discovery of PLM-102, a highly potent 3rd generation FLT3 inhibitor, in drug-resistant FLT3-ITD-TKD mutated acute myeloid leukemia

Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia

Discovery of a Potent and Selective FLT3 Inhibitor ( Z )- N -(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1 H -pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia.

Discovery of a First-in-class CDK2 Selective Degrader for AML Differentiation Therapy

Preclinical Characterization of Danatinib As a Novel FLT3 Inhibitor with Excellent Efficacy Against Resistant Acute Myeloid Leukemia.

A Combinatorial Therapeutic Approach to Enhance FLT3-ITD AML Treatment.